Recruiting

64Cu-DOTA-ECL1i

Sponsor:

University of Pennsylvania

Code:

NCT07548099

Conditions

Abdominal Aortic Aneurysm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

64Cu-DOTA-ECL1i

Study Details

Brief summary:

This research study is being conducted to test how an imaging drug called 64Cu-DOTA-ECL1i can be used to image an abdominal aortic aneurysm. 64Cu-DOTA-ECL1i is a drug used with an imaging test called a PET/CT (Positron Emission Tomography/Computed Tomography).

The aim is to collect data using a new imaging drug called 64Cu-DOTA-ECL1i that may be able to create images of inflammation in the aorta, which is thought to be important in how aneurysms grow and develop and to understand how consistent these scans are across time and what might affect the inflammation.

Conditions

Abdominal Aortic Aneurysm

Study ID

NCT07548099

Start date

Apr 30, 2026

Status verified date

May, 2026

Completion date

Apr 30, 2029

Anticipated

Primary completion date

Apr 30, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

1. Participants will be at least 18 years of age
2. Have an established diagnosis of abdominal aortic aneurysm based on standard clinical criteria or are an age matched control with absence of known AAA.
3. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion Criteria:

1. Females who are pregnant or breast feeding at the time of the PET/CT scan will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential before the injection of radiotracer.
2. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
3. Patients with chronic renal disease whose GFR is less than 40 mL/min/1.73m² at the time of enrollment.
4. Documented allergy to iodinated contrast
5. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study
6. Less than 6 months life expectancy as deemed by the treating physician at the time of initial enrollment.

Study Design

Enrollment

30 participants

Anticipated

Interventions and Outcome Measures

Arms

Participants diagnosed with Abdominal Aortic Aneurysm (AAA)

Established diagnosis of abdominal aortic aneurysm based on standard clinical criteria.

Control Group

Age-matched participants without a diagnosis of AAA as a control group.

Interventions

64Cu-DOTA-ECL1i

The radiotracer 64Cu-DOTA-ECL1i will be used to assess the aortic wall in individuals with AAA and age-matched participants without a diagnosis of AAA as a control group.

Primary outcome measure

  • • Measure uptake of 64Cu-DOTA-ECL1 [ Time Frame: 3 months ]

Central Contacts and Locations

Locations

Penn Medicine; Perelman School of Medicine

Recruiting

Philadelphia, Pennsylvania, United States, 19104

More Information

Sponsor

University of Pennsylvania

Last update posted

May 22, 2026

Last verified

May, 2026

Keywords

  • aortic aneurysm
  • aortic inflammation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by University of Pennsylvania on 2026-05-22.